Literature DB >> 32422228

Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk.

T Jespersen1, L T Møllehave2, B H Thuesen2, T Skaaby2, P Rossing3, U Toft2, N R Jørgensen4, B L Corfixen5, J Jakobsen6, M Frimodt-Møller7, A Linneberg8.   

Abstract

BACKGROUND: Dephosphorylated uncarboxylated matrix Gla-protein (dp-ucMGP) is a biomarker of functional vitamin K status. High plasma dp-ucMGP concentrations reflect a low vitamin K status and have been related to vascular calcification. Our aims were to assess plasma levels of dp-ucMGP and their association with cardiovascular risk in a general population.
METHODS: Plasma dp-ucMGP measurements were performed using the IDS-iSYS InaKtif MGP assay in 491 consecutive participants in a Danish general population study (229 males and 262 females, aged 19-71 years). Multivariable linear and logistic regressions were used to assess the association between dp-ucMGP levels and cardiovascular risk factors.
RESULTS: Mean ± standard deviation (SD) for dp-ucMGP was 465 ± 181 pmol/L, and upper 95th percentile was 690 pmol/L. In logistic regression analyses, an increase in dp-ucMGP category (<300, 300-399, 400-499, ≥500 pmol/L) was positively associated with obesity, odds ratio (OR) 2.27 (95% confidence interval (CI) 1.54-3.33), history of cardiovascular disease, OR 1.77 (CI 1.02-3.05), and above-median estimated pulse wave velocity (ePWV), OR 1.54 (CI 1.21-1.96), when adjusted for age, sex, and lifestyle factors. 1 SD increase in diastolic and systolic blood pressure (BP) corresponded to a 5.5% (CI 2.9-8.0%) and 4.7% (CI 2.1-7.4%) increase in dp-ucMGP, respectively, when adjusted for age and sex.
CONCLUSION: Plasma dp-ucMGP levels were positively associated with obesity, BP, ePWV, and history of cardiovascular disease. These findings support that dp-ucMGP is a biomarker of cardiovascular risk, and that vitamin K status could play a role in vascular calcification. The strong association with obesity deserves further attention.
Copyright © 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk; Matrix Gla protein; Vitamin K; dp-ucMGP

Mesh:

Substances:

Year:  2020        PMID: 32422228     DOI: 10.1016/j.clinbiochem.2020.05.005

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Vitamin K & D Deficiencies Are Independently Associated With COVID-19 Disease Severity.

Authors:  Ankita P Desai; Sahera Dirajlal-Fargo; Jared C Durieux; Heather Tribout; Danielle Labbato; Grace A McComsey
Journal:  Open Forum Infect Dis       Date:  2021-07-29       Impact factor: 3.835

2.  Comment on Sobczyk, M.K.; Gaunt, T.R. The Effect of Circulating Zinc, Selenium, Copper and Vitamin K1 on COVID-19 Outcomes: A Mendelian Randomization Study. Nutrients 2022, 14, 233.

Authors:  Rob Janssen; Cees Vermeer; Jona Walk; Allan Linneberg
Journal:  Nutrients       Date:  2022-03-07       Impact factor: 5.717

3.  Urinary matrix Gla protein is associated with mortality risk in Flemish population: A prospective study.

Authors:  Dongmei Wei; Jesus Melgarejo; Thomas Vanassche; Lucas Van Aelst; Stefan Janssens; Peter Verhamme; Zhen-Yu Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-22

Review 4.  Perspective: Evidence before Enthusiasm-A Critical Review of the Potential Cardiovascular Benefits of Vitamin K.

Authors:  M Kyla Shea; Kathleen L Berkner; Guylaine Ferland; Xueyan Fu; Rachel M Holden; Sarah L Booth
Journal:  Adv Nutr       Date:  2021-06-01       Impact factor: 8.701

5.  The Association of Low Vitamin K Status with Mortality in a Cohort of 138 Hospitalized Patients with COVID-19.

Authors:  Allan Linneberg; Freja Bach Kampmann; Simone Bastrup Israelsen; Liv Rabøl Andersen; Henrik Løvendahl Jørgensen; Håkon Sandholt; Niklas Rye Jørgensen; Sanne Marie Thysen; Thomas Benfield
Journal:  Nutrients       Date:  2021-06-09       Impact factor: 5.717

6.  Vitamin K Supplementation for the Prevention of Cardiovascular Disease: Where Is the Evidence? A Systematic Review of Controlled Trials.

Authors:  Caitlyn Vlasschaert; Chloe J Goss; Nathan G Pilkey; Sandra McKeown; Rachel M Holden
Journal:  Nutrients       Date:  2020-09-23       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.